GordonMD Global Investments LP
Follow13F filer, CIK 2039349, Beverely Hills, CA
GordonMD Global Investments LP reported $166,469,374 across 14 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 85.68% of the portfolio.
Accepted , ingested 13F-HR 0000919574-26-007964
- Period
- 2026-09-30
- Reported value
- $166M
- Holdings
- 14
- Top 10 weight
- 85.68%
- New
- 3
- Sold out
- 5
Part of the filer group GordonMD Global Investments LP
GordonMD Global Investments GP LLCGordon Craig D
- GordonMD Global Investments GP LLC
- Gordon Craig D
- GordonMD Long Biased GP LLC
- GordonMD Long Biased Master Fund LP
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| TEVAnew | +379,520 | $15M |
| PYXSadded | +5,517,000 | $12.9M |
| TNGXnew | +1,852,495 | $9.02M |
| ADRXnew | +450,000 | $8.97M |
| KYTXadded | +276,500 | $1.88M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| TEVAexited | -2,402,495 | -$16.4M |
| TSHAreduced | -475,185 | -$11.9M |
| RAREexited | -289,101 | -$9.65M |
| VIRreduced | -550,000 | -$6.15M |
| SIONexited | -136,000 | -$5.98M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0000919574-26-007964, largest first. % of portfolio is the value over $166,469,374, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| PYXSPYXIS ONCOLOGY INC | 15,541,909 | $36.2M | 21.75% | +5,517,000 | 2026-10-01, 13G/A: 20,441,948 shares, 16.4% of the class, 13G/A filed 2026-10-09 | Timeline | |
| KYTXKYVERNA THERAPEUTICS INC | 4,521,318 | $30.7M | 18.47% | +276,500 | Timeline | ||
| TEVATEVA PHARMACEUTICAL INDS LTD | 379,520 | $15M | 9.03% | new | Timeline | ||
| CLDXCELLDEX THERAPEUTICS INC NEW | 279,720 | $9.07M | 5.45% | 0 | Timeline | ||
| TNGXTANGO THERAPEUTICS INC | 1,852,495 | $9.02M | 5.42% | new | Timeline | ||
| VIRVIR BIOTECHNOLOGY INC | 803,552 | $8.98M | 5.4% | -550,000 | Timeline | ||
| ADRXADARX PHARMACEUTICALS INC | 450,000 | $8.97M | 5.39% | new | Timeline | ||
| ALLOALLOGENE THERAPEUTICS INC | 5,298,000 | $8.48M | 5.09% | 0 | Timeline | ||
| BLCOBAUSCH PLUS LOMB CORP | 475,472 | $8.08M | 4.86% | -98,000 | Timeline | ||
| EDITEDITAS MEDICINE INC | 3,127,000 | $8.04M | 4.83% | 0 | Timeline | ||
| INCYINCYTE CORP | 51,080 | $6.2M | 3.72% | +7,780 | Timeline | ||
| TSHATAYSHA GENE THERAPIES INC | 248,000 | $6.19M | 3.72% | -475,185 | Timeline | ||
| AMGNAMGEN INC | 14,512 | $6.12M | 3.67% | -5,700 | Timeline | ||
| SRRKSCHOLAR ROCK HLDG CORP | 110,500 | $5.34M | 3.21% | -22,000 | Timeline |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000919574-26-007964 | base | 2026-11-16 |